Authors
Latest:
The Next Chapter in RCC Recontextualizes Treatment ConsiderationsRenal cell carcinoma is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Native patient populations.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder CancerSaeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.
Latest:
Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDACSafi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Latest:
Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and BeyondChimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.
Latest:
Unmet Needs and Future Perspectives in Multiple Myeloma CareThe panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
Latest:
Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple MyelomaSagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.
Latest:
Investigational Agents for Relapsed/Refractory MyelomaKeith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Latest:
Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung CancerSagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.
Latest:
Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLCSai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).
Latest:
Dr. Ou on the FDA Approval of Pembrolizumab in SCLCSai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).
Latest:
Dr. Ou on Alectinib as Treatment for NSCLCSai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.
Latest:
Dr. Ahmed on Optimizing Treatment With Axi-Cel in LBCLSairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.
Latest:
Dr. Al-Batran on Future of Treatment in Gastric CancerSalah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.
Latest:
Sam Donaldson on the Need for Optimistic DoctorsFormer ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.
Latest:
Finding Time: A Day in the Life of an Academic OncologistWe all have to balance competing demands on our time. But as an academic oncologist, I have to keep a foot in 2 worlds, research and clinical, while still keeping my balance.
Latest:
Dr. Chang on Efforts to Improve Quality of Life in Prostate CancerSam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.
Latest:
Immunotherapy at the Forefront of ALL Treatment, Expert SaysMajor advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.
Latest:
Dr. Roychowdhury on FGFR Mutations in Intrahepatic CholangiocarcinomaSameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.
